多发性骨髓瘤葡萄糖代谢与细胞增殖评估:18F-FDG与18F-FLT PET/CT联合成像的首次报告
该先导研究纳入8例多发性骨髓瘤患者(4例症状性MM、4例冒烟型MM),连续两天行18F-FDG与18F-FLT PET/CT静态全身及下腹盆腔动态扫描。18F-FDG PET/CT检出5例患者共48个MM指示性病灶,18F-FLT PET/CT仅检出2例患者共17个病灶,且常见FDG局灶摄取增高而FLT摄取低于周围骨髓的不匹配现象。作者结论认为18F-FLT似乎不适合作为MM诊断的单一示踪剂,并需扩大样本进一步研究。
要点
- 18F-FDG PET/CT检出5例患者共48个MM指示性病灶,18F-FLT PET/CT仅检出2例患者共17个病灶。
- 常见FDG局灶摄取增高而FLT摄取低于周围骨髓的不匹配表现。
- 18F-FLT PET/CT骨髓背景活性高,进一步增加骨髓病灶评估难度。
核心结论
- 尽管该先导研究分析的患者数量有限,试验的初步结果表明18F-FLT似乎不适合作为多发性骨髓瘤诊断的单一示踪剂。
- 需要开展更大患者人群的进一步研究以推广本文所呈现的结果。
研究设计与样本
- 该研究为先导研究,纳入8例患者,其中4例为症状性多发性骨髓瘤、4例为冒烟型多发性骨髓瘤。
- 所有患者连续两天接受18F-FDG PET/CT与18F-FLT PET/CT成像,包括静态全身PET/CT和下腹盆腔动态PET/CT。
- PET/CT评估基于定性评价、半定量SUV计算以及基于两组织室模型的定量分析。
主要发现
- 18F-FDG PET/CT在5例患者中显示局灶性18F-FDG高摄取的MM指示性骨髓病灶,而18F-FLT PET/CT仅在2例患者中显示局灶性18F-FLT高摄取的骨髓瘤指示性病灶。
- 18F-FDG PET/CT共检出48个18F-FDG高摄取的局灶性MM指示性病灶,18F-FLT PET/CT共检出17个18F-FLT高摄取的局灶性MM指示性病灶。
- 18F-FDG PET/CT检出的骨髓瘤指示性病灶数量显著高于18F-FLT PET/CT。
- 常见表现为局灶性18F-FDG摄取增高与18F-FLT摄取减低(低于周围骨髓)的不匹配。
- 18F-FLT PET/CT骨髓背景活性高,进一步增加骨髓病灶评估的难度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该先导研究分析的患者数量有限。
- 需要开展更大患者人群的进一步研究以推广本文所呈现的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the significant upgrading in recent years of the role of 18F-FDG PET/CT in multiple myeloma (MM) diagnostics, there is a still unmet need for myeloma-specific radiotracers. 3'-Deoxy-3'-[18F]fluorothymidine (18F-FLT) is the most studied cellular proliferation PET agent, considered a potentially new myeloma functional imaging tracer. The aim of this pilot study was to evaluate 18F-FLT PET/CT in imaging of MM patients, in the context of its combined use with 18F-FDG PET/CT. RESULTS: Eight patients, four suffering from symptomatic MM and four suffering from smoldering MM (SMM), were enrolled in the study. All patients underwent 18F-FDG PET/CT and 18F-FLT PET/CT imaging by means of static (whole body) and dynamic PET/CT of the lower abdomen and pelvis (dPET/CT) in two consecutive days. The evaluation of PET/CT studies was based on qualitative evaluation, semi-quantitative (SUV) calculation, and quantitative analysis based on two-tissue compartment modeling. 18F-FDG PET/CT demonstrated focal, 18F-FDG avid, MM-indicative bone marrow lesions in five patients. In contrary, 18F-FLT PET/CT showed focal, 18F-FLT avid, myeloma-indicative lesions in only two patients. In total, 48 18F-FDG avid, focal, MM-indicative lesions were detected with 18F-FDG PET/CT, while 17 18F-FLT avid, focal, MM-indicative lesions were detected with 18F-FLT PET/CT. The number of myeloma-indicative lesions was significantly higher for 18F-FDG PET/CT than for 18F-FLT PET/CT. A common finding was a mismatch of focally increased 18F-FDG uptake and reduced 18F-FLT uptake (lower than the surrounding bone marrow). Moreover, 18F-FLT PET/CT was characterized by high background activity in the bone marrow compartment, further complicating the evaluation of bone marrow lesions. Semi-quantitative evaluation revealed that both SUVmean and SUVmax were significantly higher for 18F-FLT than for 18F-FDG in both MM lesions and reference tissue. SUV values were higher in MM lesions than in reference bone marrow for both tracers. CONCLUSIONS: Despite the limited number of patients analyzed in this pilot study, the first results of the trial indicate that 18F-FLT does not seem suitable as a single tracer in MM diagnostics. Further studies with a larger patient population are warranted to generalize the herein presented results.
引用
- Sachpekidis C, Goldschmidt H, Kopka K, et al. Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging. EJNMMI Res. 2018. PMID: 29633046. doi:10.1186/s13550-018-0383-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。